Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 2, 2008, Pages 749-758

  Amrite, Aniruddha C ^a,c   Kompella, Uday B ^a,b,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c IQVIA   (United States)

^d NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; FLURBIPROFEN; ROFECOXIB; VASCULOTROPIN;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IC 50; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA CELL; RETINA MACULA AGE RELATED DEGENERATION;

CELL LINE; CELL PROLIFERATION; CHOROID; CYCLOOXYGENASE 2; ENDOTHELIAL CELLS; HUMANS; PYRAZOLES; RETINAL PIGMENTS; SULFONAMIDES;

EID: 38749146468     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.128918     Document Type: Article

References (43)

1. Amrite AC, Ayalasomayajula SP, Cheruvu NP, and Kompella UB (2006) Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci 47:1149-1160.
2. Amrite AC, Edelhauser HF, and Kompella UB (2007) Modeling of corneal and retinal pharmacokinetics following periocular administration. Invest Ophthalmol Vis Sci 49:320-332.
3. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, et al. (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885-895.
4. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, and Ogier-Denis E (2002) Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277:27613-27621.
5. Ayalasomayajula SP and Kompella UB (2003) Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol 458:283-289.
6. Ayalasomayajula SP and Kompella UB (2004) Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res 21:1797-1804.
7. Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E, and Bundred NJ (2007) Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 96:575-582.
8. Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, Osen E, Nguyen B, Tsing S, Bach C, Freire J, et al. (1994) Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1209:130-139.
9. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, and Mukherjee P (2005) Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 7:R422-R435.
10. Benjamin LE, Golijanin D, Itin A, Pode D, and Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165.
11. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, et al. (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873-884.
12. Cheruvu NP, Amrite AC, and Kompella UB (2007) Effect of eye pigmentation on trans-scleral drug delivery. Invest Ophthalmol Vis Sci 49:333-341.
13. Davies NM, McLachlan AJ, Day RO, and Williams KM (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38:225-242.
14. Desai KGH, Kulkarni AR, and Aminabhavi TM (2003) Solubility of rofecoxib in the presence of methanol, ethanol, and sodium lauryl sulfate at (298.15, 303.15, and 308.15) K. J Chem Eng Data 48:942-945.
15. Dvory-Sobol H, Cohen-Noyman E, Kazanov D, Figer A, Birkenfeld S, Madar-Shapiro L, Benamouzig R, and Arber N (2006) Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer 42:422-426.
16. Ferris FL 3rd, Fine SL, and Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102:1640-1642.
17. Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, and Wozniak A (2007) Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol 2:299-305.
18. Gerber HP, Dixit V, and Ferrara N (1998a) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273:13313-13316.
19. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, and Ferrara N (1998b) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343.
20. Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, et al. (2007) Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99:545-557.
21. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, and Chen CS (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397-11403.
22. Johnson AJ, Song X, Hsu A, and Chen C (2001) Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul 41:221-235.
23. Jonas JB and Neumaier M (2007) Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema. Ophthalmic Res 39:139-142.
24. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, and Chen CS (2004) 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 64:1444-1451.
25. Lai GH, Zhang Z, and Sirica AE (2003) Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther 2:265-271.
26. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, and Masferrer JL (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62:625-631.
27. Li P and Zhao L (2003) Solubilization of flurbiprofen in pH-surfactant solutions. J Pharm Sci 92:951-956.
28. Lin HP, Kulp SK, Tseng PH, Yang YT, Yang CC, Chen CS, and Chen CS (2004) Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol Cancer Ther 3:1671-1680.
29. Nam DH, Park K, Park C, Im YH, Kim MH, Lee S, Hong SC, Shin HJ, Kim JH, Eoh W, et al. (2004) Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. Oncol Rep 11:263-268.
30. Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, and Geisslinger G (2004) Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 68:341-350.
31. Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, et al. (1999) The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)- furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 9:1773-1778.
32. Raghava S and Kompella UB (2007) AQ4, an antitumor anthracenedione, inhibits endothelial cell proliferation and vascular endothelial growth factor secretion: implications for the therapy of ocular neovascular disorders. Eur J Pharmacol 568:68-74.
33. Riazi-Esfahani M, Peyman GA, Aydin E, Kazi AA, Kivilcim M, and Sanders DR (2006) Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model. Cornea 25:801-805.
34. Sarkar FH, Adsule S, Li Y, and Padhye S (2007) Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem 7:599-608.
35. Seddon JM and Chen CA (2006) Epidemiology of age related macular degeneration, in Retina (Ryan SJ ed) pp 1017-1028, Elsevier-Mosby, Philadelphia, PA.
36. Seedher N and Bhatia S (2003) Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech 4:E33.
37. Simmons DL, Botting RM, and Hla T (2004) Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387-437.
38. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, and Isakson PC (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 95:13313-13318.
39. Soo RA, Wu J, Aggarwal A, Tao Q, Hsieh W, Putti T, Tan KB, Low JS, Lai YF, Mow B, et al. (2006) Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol 17:1625-1630.
40. Spaide R (2006) Etiology of late age related macular disease, in Age Related Macular Degeneration (Alfaro VD, Liggett PE, Mieler WF, Quiroz-Mercado H, Jager R, and Tano Y eds) pp 23-39, Lippincot Williams & Wilkins, Philadelphia, PA.
41. Wu T, Leng J, Han C, and Demetris AJ (2004) The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 3:299-307.
42. Yang HM, Kim HS, Park KW, You HJ, Jeon SI, Youn SW, Kim SH, Oh BH, Lee MM, Park YB, et al. (2004) Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110:301-308.
43. Zhang Z, Lai GH, and Sirica AE (2004) Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 39:1028-1037.